Am. J. Respir. Crit. Care Med., Volume 160, Number 6, December 1999, 1824-1829

Mirtazapine, a Mixed-Profile Serotonin Agonist/Antagonist, Suppresses Sleep Apnea in the Rat

DAVID W. CARLEY and MIODRAG RADULOVACKI

Departments of Medicine, Pharmacology, and Bioengineering, University of Illinois at Chicago, Chicago, Illinois

Serotonin enhancing drugs, including L-tryptophan and, more recently, fluoxetine and paroxetine, have been tested as pharmacologic treatments for sleep apnea syndrome. Although some patients have demonstrated reduced apnea expression after treatment with these compounds, this improvement has been restricted to nonrapid eye movement (NREM) sleep, with some patients showing no improvement. This study reports the effects of mirtazapine, an antidepressant with 5-HT₁ agonist as well as 5-HT₂ and 5-HT₃ antagonist effects, on sleep and respiration in an established animal model of central apnea. We studied nine adult male Sprague-Dawley rats chronically instrumented for sleep staging. In random order on separate days, rats were recorded after intraperitoneal injection of: (1) saline, (2) 0.1 mg/kg +/ mirtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine. With respect to saline injections, mirtazapine at all three doses reduced apnea index during NREM sleep by more than 50% (p < 0.0001) and during REM sleep by 60% (p < 0.0001) for at least 6 h. In association with this apnea suppression normalized inspiratory minute ventilation increased during all wake/sleep states (p < 0.001 for each state). The duration of NREM sleep was unaffected by any dose of mirtazapine (p = 0.42), but NREM EEG delta power was increased by more than 30% at all doses (p = 0.04), indicating improved NREM sleep consolidation after mirtazapine injection. We conclude that mirtazapine, over a 50-fold dose range, significantly reduces central apnea expression during NREM and REM sleep in the rat. The efficacy of this compound to suppress apnea in all sleep stages most probably arises from its mixed agonist/antagonist profile at serotonin receptors. The implications of these findings for the management of sleep apnea syndrome must be verified by appropriate clinical trials. Carley DW, Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat.

This article has been cited by other articles:

				R. C. Heinzer, D. P. White, A. S. Jordan, Y. L. Lo, L. Dover, K. Stevenson, and A. Malhotra Trazodone increases arousal threshold in obstructive sleep apnoea Eur. Respir. J., June 1, 2008; 31(6): 1308 - 1312. [Abstract] [Full Text] [PDF]

				B. Buyse and the participants of working group 2 Treatment effects of sleep apnoea: where are we now? Eur. Respir. Rev., December 1, 2007; 16(106): 146 - 168. [Abstract] [Full Text] [PDF]

				T. Ogasa, A. D. Ray, C. P. Michlin, G. A. Farkas, B. J. B. Grant, and U. J. Magalang Systemic Administration of Serotonin 2A/2C Agonist Improves Upper Airway Stability in Zucker Rats Am. J. Respir. Crit. Care Med., October 1, 2004; 170(7): 804 - 810. [Abstract] [Full Text] [PDF]

				P. Fenik and S. C. Veasey Pharmacological Characterization of Serotonergic Receptor Activity in the Hypoglossal Nucleus Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 563 - 569. [Abstract] [Full Text] [PDF]